Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 5462 (Primary)
  • Indications Cardiovascular disorders
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca

    • Most Recent Events

    • 28 Aug 2023 Results assessing the safety, tolerability, and pharmacokinetics of AZD5462 in single ascending dose and multiple ascending dose administration in healthy participants, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
    • 07 Oct 2022 Status changed from recruiting to completed.
    • 01 Sep 2022 Planned End Date changed from 26 Sep 2022 to 20 Sep 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top